| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestra | Aachen, Heidelberg, Tübingen | Phase II | rekrutiert |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of | Düsseldorf, Essen, Georgsmarienhütte | Phase III | rekrutiert |
| A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to | Ulm | Phase III | rekrutiert |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs | Köln, Dresden, Essen | Phase III | rekrutiert |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Essen, Dresden, Berlin | Phase I / Phase II | rekrutiert |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early | Mannheim, Ulm, Augsburg | Phase III | rekrutiert |
| A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | Erlangen | Phase I | rekrutiert |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abe | Tübingen, Essen, Hamburg | Phase I / Phase II | rekrutiert |
| A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies | Köln, Essen, Karlsruhe | Phase IV | rekrutiert |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in | Ulm, Erlangen, Berlin | Phase III | rekrutiert |
| A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Ca | Berlin, Dresden, Essen | Phase II | rekrutiert |
| AXillary Surgery After NeoAdjuvant Treatment | Esslingen am Neckar | — | rekrutiert |
| Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positi | Heidelberg, Osnabrück, Wuppertal | ohne Phasenangabe | rekrutiert |
| Breast Cancer Registry Platform | Many Locations | — | rekrutiert |
| Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Ad | Aachen, Augsburg, Bad Nauheim | Phase III | rekrutiert |
| Cognitive Training and Brain Stimulation in Women With Post-chemotherapy Cognitive Impairment | Greifswald | ohne Phasenangabe | rekrutiert |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Re | Erlangen, Mainz, Bottrop | Phase IV | rekrutiert |
| Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Brea | Berlin, Bremen, Dortmund | Phase II | rekrutiert |
| Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcome | Münster | ohne Phasenangabe | rekrutiert |
| Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer | Dessau | Phase II | rekrutiert |
| Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer | Freiburg im Breisgau, Paderborn, Ravensburg | — | rekrutiert |
| Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac | Tübingen | ohne Phasenangabe | rekrutiert |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antine | Erlangen | Phase I / Phase II | rekrutiert |
| Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surr | Frankfurt am Main, Heidelberg, Rostock | ohne Phasenangabe | rekrutiert |
| Large Language Models to Aid Gynecological Oncology Treatment | Marburg | ohne Phasenangabe | rekrutiert |
| MEthods for LOcalization of Different Types of Breast Lesions | Lübeck | — | rekrutiert |
| Magseed Pro(R)/ Sentimag(R) Gen3 | Bottrop, Frankfurt am Main, München | ohne Phasenangabe | rekrutiert |
| Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Ge | Mannheim, Tübingen, Esslingen am Neckar | Phase III | rekrutiert |
| Multicenter Cardiac Decision Impact Study in People With Breast Cancer | München | ohne Phasenangabe | rekrutiert |
| NeoRad Breast Cancer Study | Ahaus, Bad Homburg vor der Höhe, Berlin | Phase III | rekrutiert |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cance | Karlsruhe, Krefeld, Velbert | Phase III | rekrutiert |
| PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and | Amberg, Ansbach, Apolda | — | rekrutiert |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced B | Frankfurt am Main, Düsseldorf, Torgau | Phase III | rekrutiert |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negativ | Düsseldorf, Mainz, Saarbrücken | Phase III | rekrutiert |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally A | Aschaffenburg, Bottrop, Dresden | Phase III | rekrutiert |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in | Augsburg, Bayreuth, Berlin | Phase III | rekrutiert |
| Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib | Köln, Essen, Mönchengladbach | Phase III | rekrutiert |
| Predicting Cancer Risk With Digital and Molecular Markers | Please Refer to Project Homepage For Details (see Link Below) | ohne Phasenangabe | rekrutiert |
| Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and H | Tübingen | — | rekrutiert |
| Seroma of the Mammary Gland | Augsburg | ohne Phasenangabe | rekrutiert |
| Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer | Ulm | ohne Phasenangabe | rekrutiert |
| TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes | Essen | — | rekrutiert |
| The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Stud | Tübingen | — | rekrutiert |
| ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography. | Heidelberg | ohne Phasenangabe | rekrutiert |
| To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET | Essen | — | rekrutiert |
| Widening Aims and Giving Patients a Voice for Expanded Structures in Breast Cancer Care Jointly | Augsburg | — | rekrutiert |